IN ORAL ANTICOAGULATION, CONSIDER BOTH CLINICAL CONCERNS AND LIFESTYLE FACTORS

LIXIANA® (edoxaban) is a once-daily, oral, direct factor Xa inhibitor that combines:

Highly effective stroke/systemic embolism prevention in
ENGAGE AF-TIMI 48

Provided a highly effective prevention of stroke and systemic embolism.1,§

Superior reduction of major bleeding in ENGAGE AF-TIMI 48

Superior to warfarin in reducing the risk of major bleeding events.1,*

  • *

    Major bleeding in nonsurgical patients was defined as2

    1. Fatal bleeding, and/or
    2. Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or
    3. Bleeding causing a fall in haemoglobin level of 20 g/L-1 (1.24 mml/L-1) or more, or leading to transfusing of 2 or more units of whole blood or red cells.
  • §

    One or more of the following factors: moderate renal impairment (creatinine clearance of 30-50 mL/min), low body weight (≤60 kg/132 lbs), concomitant use of P-glycoprotein inhibitors (eg, cyclosporine, dronedarone, ketoconazole, erythromycin).